Midatech Pharma PLC Announces Registration Statement Declared Effective
Midatech Pharma PLC announced that the U.S. SEC has declared effective its registration statement on Form F-1 for the resale of up to 12,695,445 ordinary shares, represented by 2,539,091 American Depositary Shares (ADSs). These shares are connected to multiple warrant exercises at various prices, including $6.25 and $2.05 per ADS. While the registration allows stockholders to sell their ADSs or ordinary shares, the company will not receive proceeds from these sales. However, it will receive funds upon the cash exercise of the warrants. Additional details are available on the SEC's website.
- SEC's effective registration for the resale of 12,695,445 ordinary shares enhances market liquidity.
- The potential exercise of warrants could provide additional funds to the company.
- None.
ABINGDON, OXFORDSHIRE / ACCESSWIRE / August 14, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that the U.S. Securities and Exchange Commission ("SEC") has declared effective the Company's registration statement on Form F-1 (the "Registration Statement") relating to the permitted resale of up to 12,695,445 ordinary shares, nominal value 0.1p each, in the Company ("Ordinary Shares") represented by 2,539,091 American Depositary Shares (the "ADSs") held by certain stockholders of the Company named in the registration statement that are issuable upon the exercise of previously issued warrants as follows:
- 3,150,000 Ordinary Shares represented by 630,000 ADSs issuable upon exercise of warrants at
$6.25 per ADS. These warrants were issued pursuant to a US Registered Direct Offering in October 2019; - 9,545,455 Ordinary Shares represented by 1,818,182 ADSs issuable upon exercise of warrants at
$2.05 per ADS. These warrants were issued pursuant to a US Registered Direct Offering in May 2020; and - 454,549 Ordinary Shares represented by 90,909 ADSs issuable upon exercise of warrants at
$2.06 25 per ADS. These warrants were also issued pursuant to a US Registered Direct Offering in May 2020.
In addition, in May 2020, warrants were issued to certain UK investors in respect 3,213,957 Ordinary Shares exercisable at £0.34 per share. These warrants became exercisable upon the effectiveness of the Registration Statement.
The Registration Statement, while effective, allows the stockholders named in the Registration Statement to publicly resell the ADSs or Ordinary Shares. The Company will not receive any proceeds from the sale of the ADSs or Ordinary Shares by the stockholders. Upon the cash exercise of the warrants, the Company will receive the exercise price of the warrants.
The Registration Statement may be accessed through the SEC's website at www.sec.gov. A copy of the prospectus relating to the offering may also be accessed through the SEC's website at www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
For more information, please contact:
Midatech Pharma PLC |
Stephen Stamp, CEO, CFO |
Tel: +44 (0)1235 888300 |
Panmure Gordon (UK) Limited (Nominated Adviser and Broker) |
Freddy Crossley, Emma Earl (Corporate Finance) |
James Stearns (Corporate Broking) Tel: +44 (0)20 7886 2500 |
Turner Pope Investments (TPI) Limited (Joint Broker) |
Andrew Thacker (Corporate Broking) |
Tel: +44(0)20 3657 0050 |
IFC Advisory Limited (Financial PR and UK Investor Relations) |
Tim Metcalfe / Graham Herring |
Tel: +44 (0)20 3934 6630 |
Edison Group (US Investor Relations) Megan Paul |
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, any payments that may be received as a result of the exercise of the warrants.
Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Midatech Pharma PLC
View source version on accesswire.com:
https://www.accesswire.com/601696/Midatech-Pharma-PLC-Announces-Registration-Statement-Declared-Effective
FAQ
What does the SEC's effective registration mean for Midatech Pharma (MTP)?
How many ordinary shares can be resold by Midatech Pharma shareholders?
What are the exercise prices of the warrants related to Midatech Pharma (MTP)?
Will Midatech Pharma receive proceeds from the resale of ADSs?
